日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Heart failure outcomes and empagliflozin effects in patients with heart failure and reduced ejection fraction in sinus rhythm or atrial fibrillation: Data from EMPEROR-Reduced

心力衰竭结局及恩格列净对窦性心律或房颤伴射血分数降低的心力衰竭患者的疗效：来自 EMPEROR-Reduced 研究的数据

期刊:European Journal of Heart Failure
影响因子:
doi:10.1002/ejhf.70021
Böhm, Michael; Butler, Javed; Abdin, Amr; Filippatos, Gerasimos; Ferreira, João Pedro; Pocock, Stuart J; Brueckmann, Martina; Ofstad, Anne Pernille; Schueler, Elke; Wanner, Christoph; Zannad, Faiez; Anker, Stefan D; Packer, Milton
心力衰竭
心血管
发表日期：2025
文献求助 收藏

Kidney and heart failure events are bidirectionally associated in patients with type 2 diabetes and cardiovascular disease

在2型糖尿病和心血管疾病患者中，肾衰竭和心力衰竭事件呈双向关联。

期刊:Esc Heart Failure
影响因子:3.7
doi:10.1002/ehf2.14601
Sharma, Abhinav; Inzucchi, Silvio E; Testani, Jeffrey M; Ofstad, Anne Pernille; Fitchett, David; Mattheus, Michaela; Verma, Subodh; Zannad, Faiez; Wanner, Christoph; Kraus, Bettina J
心血管疾病
心血管
代谢
糖尿病
心力衰竭
发表日期：2024
文献求助 收藏

Empagliflozin Use Is Associated With Lower Risk of All-Cause Mortality, Hospitalization for Heart Failure, and End-Stage Renal Disease Compared to DPP-4i in Nordic Type 2 Diabetes Patients: Results From the EMPRISE (Empagliflozin Comparative Effectiveness and Safety) Study

在北欧2型糖尿病患者中，与DPP-4抑制剂相比，恩格列净的使用与全因死亡率、心力衰竭住院率和终末期肾病风险降低相关：来自EMPRISE（恩格列净比较疗效和安全性）研究的结果

期刊:Journal of Diabetes Research
影响因子:3.4
doi:10.1155/2024/6142211
Langslet, Gisle; Nyström, Thomas; Vistisen, Dorte; Carstensen, Bendix; Grip, Emilie Toresson; Casajust, Paula; Tskhvarashvili, Giorgi; Hoti, Fabian; Klement, Riho; Karlsdotter, Kristina; Tuovinen, Mikko; Ofstad, Anne Pernille; Lajer, Maria; Shay, Christina; Koeneman, Lisette; Farsani, Soulmaz Fazeli; Niskanen, Leo; Halvorsen, Sigrun
糖尿病
心力衰竭
心血管
代谢
发表日期：2024
文献求助 收藏

The influence of diagnostic subgroups, patient- and hospital characteristics for the validity of cardiovascular diagnoses-Data from a Norwegian hospital trust

诊断亚组、患者和医院特征对心血管诊断有效性的影响——来自挪威一家医院信托机构的数据

期刊:PLoS One
影响因子:2.6
doi:10.1371/journal.pone.0302181
Rye, Cathrine Sæthern; Ofstad, Anne Pernille; Åsvold, Bjørn Olav; Romundstad, Pål Richard; Horn, Julie; Dalen, Håvard
发表日期：2024
文献求助 收藏

Weight change and clinical outcomes in heart failure with reduced ejection fraction: insights from EMPEROR-Reduced

体重变化与射血分数降低的心力衰竭临床结局：来自 EMPEROR-Reduced 研究的启示

期刊:European Journal of Heart Failure
影响因子:10.8
doi:10.1002/ejhf.2728
Anker, Stefan D; Khan, Muhammad Shahzeb; Butler, Javed; Ofstad, Anne Pernille; Peil, Barbara; Pfarr, Egon; Doehner, Wolfram; Sattar, Naveed; Coats, Andrew J S; Filippatos, Gerasimos; Ferreira, João Pedro; Zannad, Faiez; Pocock, Stuart; Packer, Milton
心力衰竭
心血管
发表日期：2023
文献求助 收藏

Baseline Cardiovascular Risk Factor Control in Patients With Type 2 Diabetes and Coronary Disease Versus Stroke: Secondary Analysis of Cardiovascular Outcome Trials

型糖尿病合并冠心病患者基线心血管危险因素控制与卒中：心血管结局试验的二次分析

期刊:Stroke
影响因子:8.9
doi:10.1161/STROKEAHA.122.042053
Balasubramanian, Priyadarshini; Kernan, Walter N; Sheth, Kevin N; Ofstad, Anne Pernille; Rosenstock, Julio; Wanner, Christoph; Zinman, Bernard; Mattheus, Michaela; Marx, Nikolaus; Inzucchi, Silvio E
代谢
糖尿病
心血管
冠心病
发表日期：2023
文献求助 收藏

Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome: Analysis of EMPA-REG OUTCOME using REDUCE-IT criteria

REDUCE-IT入选标准在大型糖尿病心血管结局试验中的普适性：EMPA-REG结局的事后亚组分析：使用REDUCE-IT标准分析EMPA-REG结局

期刊:American Journal of Preventive Cardiology
影响因子:5.9
doi:10.1016/j.ajpc.2023.100510
Verma, Subodh; Kosmopoulos, Andrew; Bhatt, Deepak L; Fitchett, David; Ofstad, Anne Pernille; Wanner, Christoph; Mattheus, Michaela; Zinman, Bernard; Lawler, Patrick R; Leiter, Lawrence A
糖尿病
RED
代谢
发表日期：2023
文献求助 收藏

Development of a tool to predict the risk of incident heart failure in a general population: the HUNT for HF risk score

开发一种预测普通人群发生心力衰竭风险的工具：HUNT HF 风险评分

期刊:Esc Heart Failure
影响因子:3.7
doi:10.1002/ehf2.14390
Ofstad, Anne Pernille; Brunborg, Cathrine; Johansen, Odd Erik; Mørkedal, Bjørn; Fagerland, Morten W; Laugsand, Lars Erik; Gullestad, Lars L; Dalen, Håvard
心血管
心力衰竭
发表日期：2023
文献求助 收藏

Empagliflozin for Heart Failure With Preserved Left Ventricular Ejection Fraction With and Without Diabetes

恩格列净治疗伴或不伴糖尿病的左心室射血分数保留型心力衰竭

期刊:Circulation
影响因子:38.6
doi:10.1161/CIRCULATIONAHA.122.059785
Filippatos, Gerasimos; Butler, Javed; Farmakis, Dimitrios; Zannad, Faiez; Ofstad, Anne Pernille; Ferreira, João Pedro; Green, Jennifer B; Rosenstock, Julio; Schnaidt, Sven; Brueckmann, Martina; Pocock, Stuart J; Packer, Milton; Anker, Stefan D
糖尿病
心力衰竭
心血管
代谢
发表日期：2022
文献求助 收藏

Empagliflozin and Decreased Risk of Nephrolithiasis: A Potential New Role for SGLT2 Inhibition?

恩格列净与肾结石风险降低：SGLT2抑制剂的潜在新作用？

期刊:Journal of Clinical Endocrinology & Metabolism
影响因子:5.1
doi:10.1210/clinem/dgac154
Balasubramanian, Priyadarshini; Wanner, Christoph; Ferreira, João Pedro; Ofstad, Anne Pernille; Elsaesser, Amelie; Zinman, Bernard; Inzucchi, Silvio E
SGLT2
肾结石
毒理研究
发表日期：2022
文献求助 收藏